Prenetics Global Ltd Annual Report - A Plain-English Investor Guide

I’ve put together this guide to help you understand how Prenetics Global Ltd performed this year. Instead of digging through dense financial filings, we’ll break down the important details so you can get a clear picture of the business.

1. What does this company do?

Prenetics is a health-tech company focused on preventative care. Their core business includes the genetic testing platform, CircleDNA, and consumer health products like their supplement line, IM8.

This year, the company focused on "spring cleaning." They sold off non-core businesses, such as Europa Sports Partners, to remove distractions. By narrowing their focus, they are prioritizing resources toward their high-growth health initiatives.

2. Financial performance

The company is in a transition phase and is currently prioritizing growth over immediate profit. They have reported losses since inception, and management expects these to continue as they invest in building their brand. The financial statements reflect the costs of restructuring and the divestment of older business units. While these sales help clean up the balance sheet, they contribute to volatility in the financial reports as the company pivots to its new model.

3. Major wins and challenges

• The Win: Streamlining. By selling off units like Europa Sports, management is narrowing the company’s scope. A more focused business model is intended to make it easier for investors to track the performance of their core products.
• The Challenge: Growing Pains. The company relies on a limited number of outside suppliers for their testing kits and supplements. Any disruption to these suppliers could impact product availability. Furthermore, the company is betting heavily on the success of new products like IM8; if these products do not gain sufficient market traction, the company will face challenges in reaching profitability.

4. Financial health and structure

As of late 2025, the company maintains a complex capital structure involving various share classes and warrants, which adds a layer of difficulty to valuing the investment. All revenue is generated outside of mainland China. While the company operates in Hong Kong, it remains outside the direct control of the mainland Chinese government. However, management notes that any future changes in regulations or their extension to Hong Kong could impact the business.

5. Key risks

• Legal Hurdles: Because the company is incorporated in the Cayman Islands and operates in Hong Kong, U.S. investors may face significant challenges in pursuing legal action against the company or its directors in U.S. courts.
• Dilution: The company retains the ability to issue additional shares to raise capital or compensate employees. This can reduce your ownership percentage and your share of potential future earnings.
• Regulatory and Data Risk: As an "emerging growth company," Prenetics provides less detailed financial and executive compensation reporting than larger, more established firms. Additionally, because the company handles sensitive health data, any security breach could result in significant fines and long-term damage to their brand reputation.

Investor Takeaway: Prenetics is currently a "high-stakes" growth play. They are betting that a leaner, more focused company can scale its health-tech products effectively. Before investing, consider whether you are comfortable with the risks associated with their current transition, the potential for share dilution, and the unique legal and regulatory environment in which they operate.